Listened to the presentation. Very well done. Apparently the reimbursement system in the US has been an obstacle in the past, encouraging over-stenting. That's changing. VERY interesting that interventional cardiologists have shifted from 80% independent to 80% hospital-based over the past 5 years.
Move to Costa Rica for manufacturing will impose 1 year of margin decrease, but is anticipated to raise margins 5% in 3 years.
I hadn't realized that avoiding the need for blood volume expansion makes IFR applicable to a significantly larger number of patients than FFR.